Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30738319 | 0.88 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BMAP4K4ADORA3 | |
| SCHEMBL20392686 | 0.88 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BMAP4K4ADORA3 | |
| SCHEMBL20392653 | 0.85 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BADORA3PDK1 | |
| SCHEMBL21569365 | 0.80 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BMAP4K4ADORA3 | |
| SCHEMBL20392542 | 0.79 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BMAP4K4 | |
| SCHEMBL20392590 | 0.78 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BMAP4K4ADORA3 | |
| SCHEMBL30738356 | 0.76 | CLK4 (0.39) | ADORA2AADORA1ADORA2BMAP4K4CLK1 | |
| SCHEMBL22179732 | 0.76 | CLK4 (0.39) | ADORA2AADORA1ADORA2BMAP4K4CLK1 | |
| SCHEMBL21621288 | 0.75 | ADORA1 (0.55) | ADORA2AADORA1MAP4K4TGFBR1EGFR | |
| SCHEMBL29947057 | 0.75 | ADORA1 (0.55) | ADORA2AADORA1MAP4K4TGFBR1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884061-B | 1,2, 4-triazine-3-amine derivatives, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-20210230138-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-07-29 | — | — | US | disclosed |
| US-20210230138-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-07-29 | — | — | US | disclosed |
| US-11014904-B2 | 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-11014904-B2 | 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-20190352278-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| US-20190352278-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3569596-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2019-11-20 | — | — | EP | disclosed |
| EP-3569596-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2019-11-20 | — | — | EP | disclosed |
| WO-2018130184-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2018-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352278-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885ADORA2B 1/4885 |
| US-20210230138-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885ADORA2B 1/4885 |
| US-11014904-B2 | 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885ADORA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.